nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—BRAF—adrenal gland cancer	0.598	0.844	CbGaD
Nilotinib—ABCB1—adrenal gland cancer	0.111	0.156	CbGaD
Nilotinib—MAPK8—adrenal medulla—adrenal gland cancer	0.0172	0.159	CbGeAlD
Nilotinib—MAPK8—brown adipose tissue—adrenal gland cancer	0.00988	0.0917	CbGeAlD
Nilotinib—UGT1A1—urine—adrenal gland cancer	0.00311	0.0289	CbGeAlD
Nilotinib—CDC42BPB—adrenal cortex—adrenal gland cancer	0.00183	0.017	CbGeAlD
Nilotinib—FRK—gonad—adrenal gland cancer	0.0018	0.0167	CbGeAlD
Nilotinib—CDC42BPB—gonad—adrenal gland cancer	0.00152	0.0141	CbGeAlD
Nilotinib—CDC42BPB—cardiac atrium—adrenal gland cancer	0.00151	0.0141	CbGeAlD
Nilotinib—BLK—adrenal gland—adrenal gland cancer	0.00151	0.014	CbGeAlD
Nilotinib—CDC42BPB—pituitary gland—adrenal gland cancer	0.00148	0.0137	CbGeAlD
Nilotinib—TIE1—adrenal cortex—adrenal gland cancer	0.00144	0.0133	CbGeAlD
Nilotinib—MAPK8—gonad—adrenal gland cancer	0.00137	0.0127	CbGeAlD
Nilotinib—EPHA6—gonad—adrenal gland cancer	0.00137	0.0127	CbGeAlD
Nilotinib—MAPK8—pituitary gland—adrenal gland cancer	0.00134	0.0124	CbGeAlD
Nilotinib—MAPK11—adrenal gland—adrenal gland cancer	0.00133	0.0124	CbGeAlD
Nilotinib—CDC42BPB—adrenal gland—adrenal gland cancer	0.00132	0.0123	CbGeAlD
Nilotinib—CYP2C9—urine—adrenal gland cancer	0.00131	0.0122	CbGeAlD
Nilotinib—HCK—adrenal cortex—adrenal gland cancer	0.00126	0.0117	CbGeAlD
Nilotinib—EPHA3—adrenal gland—adrenal gland cancer	0.00125	0.0116	CbGeAlD
Nilotinib—MAPK8—adrenal gland—adrenal gland cancer	0.0012	0.0111	CbGeAlD
Nilotinib—TIE1—cardiac atrium—adrenal gland cancer	0.00119	0.011	CbGeAlD
Nilotinib—Ponatinib—ABCB1—adrenal gland cancer	0.00117	0.619	CrCbGaD
Nilotinib—BRAF—pituitary gland—adrenal gland cancer	0.00111	0.0103	CbGeAlD
Nilotinib—MAP4K1—adrenal gland—adrenal gland cancer	0.00109	0.0101	CbGeAlD
Nilotinib—TIE1—adrenal gland—adrenal gland cancer	0.00104	0.00963	CbGeAlD
Nilotinib—HCK—pituitary gland—adrenal gland cancer	0.00101	0.00942	CbGeAlD
Nilotinib—ABL2—pituitary gland—adrenal gland cancer	0.00101	0.00936	CbGeAlD
Nilotinib—CYP3A4—urine—adrenal gland cancer	0.000998	0.00927	CbGeAlD
Nilotinib—EPHB4—adrenal cortex—adrenal gland cancer	0.000997	0.00926	CbGeAlD
Nilotinib—BRAF—adrenal gland—adrenal gland cancer	0.000994	0.00923	CbGeAlD
Nilotinib—EPHB3—adrenal gland—adrenal gland cancer	0.000986	0.00916	CbGeAlD
Nilotinib—CYP2D6—urine—adrenal gland cancer	0.000982	0.00912	CbGeAlD
Nilotinib—EPHA2—adrenal cortex—adrenal gland cancer	0.000978	0.00909	CbGeAlD
Nilotinib—TEK—adrenal cortex—adrenal gland cancer	0.000954	0.00886	CbGeAlD
Nilotinib—EPHA4—gonad—adrenal gland cancer	0.000945	0.00878	CbGeAlD
Nilotinib—EPHA4—cardiac atrium—adrenal gland cancer	0.000944	0.00877	CbGeAlD
Nilotinib—CA3—cardiac atrium—adrenal gland cancer	0.000932	0.00866	CbGeAlD
Nilotinib—EPHA4—pituitary gland—adrenal gland cancer	0.000922	0.00856	CbGeAlD
Nilotinib—CA3—pituitary gland—adrenal gland cancer	0.000911	0.00846	CbGeAlD
Nilotinib—HCK—adrenal gland—adrenal gland cancer	0.000906	0.00842	CbGeAlD
Nilotinib—ABL2—adrenal gland—adrenal gland cancer	0.0009	0.00836	CbGeAlD
Nilotinib—MAPK14—pituitary gland—adrenal gland cancer	0.00085	0.0079	CbGeAlD
Nilotinib—FGR—pituitary gland—adrenal gland cancer	0.000847	0.00786	CbGeAlD
Nilotinib—CA14—cardiac atrium—adrenal gland cancer	0.000846	0.00786	CbGeAlD
Nilotinib—EPHB4—cardiac atrium—adrenal gland cancer	0.000825	0.00766	CbGeAlD
Nilotinib—EPHA4—adrenal gland—adrenal gland cancer	0.000824	0.00765	CbGeAlD
Nilotinib—EPHA2—cardiac atrium—adrenal gland cancer	0.000809	0.00752	CbGeAlD
Nilotinib—EPHB4—pituitary gland—adrenal gland cancer	0.000806	0.00748	CbGeAlD
Nilotinib—EPHA2—pituitary gland—adrenal gland cancer	0.00079	0.00734	CbGeAlD
Nilotinib—TEK—cardiac atrium—adrenal gland cancer	0.000789	0.00733	CbGeAlD
Nilotinib—MAP2K5—adrenal cortex—adrenal gland cancer	0.00078	0.00724	CbGeAlD
Nilotinib—TEK—pituitary gland—adrenal gland cancer	0.000771	0.00716	CbGeAlD
Nilotinib—CSF1R—adrenal cortex—adrenal gland cancer	0.000761	0.00707	CbGeAlD
Nilotinib—MAPK14—adrenal gland—adrenal gland cancer	0.000759	0.00705	CbGeAlD
Nilotinib—LCK—adrenal gland—adrenal gland cancer	0.000756	0.00702	CbGeAlD
Nilotinib—FGR—adrenal gland—adrenal gland cancer	0.000756	0.00702	CbGeAlD
Nilotinib—EPHB6—cardiac atrium—adrenal gland cancer	0.000754	0.00701	CbGeAlD
Nilotinib—CA14—adrenal gland—adrenal gland cancer	0.000739	0.00686	CbGeAlD
Nilotinib—EPHB6—pituitary gland—adrenal gland cancer	0.000737	0.00685	CbGeAlD
Nilotinib—Imatinib—ABCB1—adrenal gland cancer	0.00072	0.381	CrCbGaD
Nilotinib—EPHB4—adrenal gland—adrenal gland cancer	0.00072	0.00669	CbGeAlD
Nilotinib—PDGFRA—gonad—adrenal gland cancer	0.000716	0.00665	CbGeAlD
Nilotinib—EPHA2—adrenal gland—adrenal gland cancer	0.000706	0.00656	CbGeAlD
Nilotinib—TEK—adrenal gland—adrenal gland cancer	0.000689	0.0064	CbGeAlD
Nilotinib—PDGFRB—adrenal cortex—adrenal gland cancer	0.000675	0.00627	CbGeAlD
Nilotinib—EPHB6—adrenal gland—adrenal gland cancer	0.000658	0.00612	CbGeAlD
Nilotinib—MAP2K5—cardiac atrium—adrenal gland cancer	0.000645	0.00599	CbGeAlD
Nilotinib—CSF1R—gonad—adrenal gland cancer	0.00063	0.00586	CbGeAlD
Nilotinib—MAP2K5—pituitary gland—adrenal gland cancer	0.00063	0.00585	CbGeAlD
Nilotinib—CSF1R—cardiac atrium—adrenal gland cancer	0.00063	0.00585	CbGeAlD
Nilotinib—PDGFRA—adrenal gland—adrenal gland cancer	0.000624	0.0058	CbGeAlD
Nilotinib—CSF1R—pituitary gland—adrenal gland cancer	0.000615	0.00571	CbGeAlD
Nilotinib—ABL1—adrenal cortex—adrenal gland cancer	0.000602	0.00559	CbGeAlD
Nilotinib—KIT—gonad—adrenal gland cancer	0.000572	0.00532	CbGeAlD
Nilotinib—MAP2K5—adrenal gland—adrenal gland cancer	0.000563	0.00523	CbGeAlD
Nilotinib—PDGFRB—gonad—adrenal gland cancer	0.000559	0.00519	CbGeAlD
Nilotinib—KIT—pituitary gland—adrenal gland cancer	0.000559	0.00519	CbGeAlD
Nilotinib—PDGFRB—cardiac atrium—adrenal gland cancer	0.000558	0.00519	CbGeAlD
Nilotinib—CSF1R—adrenal gland—adrenal gland cancer	0.000549	0.0051	CbGeAlD
Nilotinib—PDGFRB—pituitary gland—adrenal gland cancer	0.000546	0.00507	CbGeAlD
Nilotinib—KIT—adrenal gland—adrenal gland cancer	0.000499	0.00463	CbGeAlD
Nilotinib—ABL1—gonad—adrenal gland cancer	0.000498	0.00463	CbGeAlD
Nilotinib—ABL1—cardiac atrium—adrenal gland cancer	0.000498	0.00462	CbGeAlD
Nilotinib—PDGFRB—adrenal gland—adrenal gland cancer	0.000487	0.00453	CbGeAlD
Nilotinib—ABL1—pituitary gland—adrenal gland cancer	0.000486	0.00452	CbGeAlD
Nilotinib—ABL1—adrenal gland—adrenal gland cancer	0.000434	0.00403	CbGeAlD
Nilotinib—CA2—adrenal cortex—adrenal gland cancer	0.00041	0.00381	CbGeAlD
Nilotinib—CA4—cardiac atrium—adrenal gland cancer	0.000409	0.0038	CbGeAlD
Nilotinib—CA4—pituitary gland—adrenal gland cancer	0.000399	0.00371	CbGeAlD
Nilotinib—ABCG2—adrenal cortex—adrenal gland cancer	0.000379	0.00352	CbGeAlD
Nilotinib—CA4—adrenal gland—adrenal gland cancer	0.000357	0.00331	CbGeAlD
Nilotinib—CYP2B6—adrenal cortex—adrenal gland cancer	0.00035	0.00325	CbGeAlD
Nilotinib—CA2—cardiac atrium—adrenal gland cancer	0.000339	0.00315	CbGeAlD
Nilotinib—CA2—pituitary gland—adrenal gland cancer	0.000331	0.00308	CbGeAlD
Nilotinib—CYP2C8—pituitary gland—adrenal gland cancer	0.000315	0.00293	CbGeAlD
Nilotinib—ABCG2—pituitary gland—adrenal gland cancer	0.000307	0.00285	CbGeAlD
Nilotinib—CA2—adrenal gland—adrenal gland cancer	0.000296	0.00275	CbGeAlD
Nilotinib—CYP2B6—gonad—adrenal gland cancer	0.00029	0.00269	CbGeAlD
Nilotinib—ABCG2—adrenal gland—adrenal gland cancer	0.000274	0.00254	CbGeAlD
Nilotinib—CYP2B6—adrenal gland—adrenal gland cancer	0.000253	0.00235	CbGeAlD
Nilotinib—ABCB1—adrenal cortex—adrenal gland cancer	0.000187	0.00174	CbGeAlD
Nilotinib—ABCB1—gonad—adrenal gland cancer	0.000155	0.00144	CbGeAlD
Nilotinib—ABCB1—pituitary gland—adrenal gland cancer	0.000151	0.0014	CbGeAlD
Nilotinib—ABCB1—adrenal gland—adrenal gland cancer	0.000135	0.00125	CbGeAlD
Nilotinib—MAPK11—Signaling Pathways—GNAS—adrenal gland cancer	1.37e-05	7.5e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IGF2—adrenal gland cancer	1.36e-05	7.49e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CDC42—adrenal gland cancer	1.36e-05	7.49e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—adrenal gland cancer	1.36e-05	7.49e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MEN1—adrenal gland cancer	1.36e-05	7.48e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—GNAS—adrenal gland cancer	1.35e-05	7.42e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—CTNNB1—adrenal gland cancer	1.34e-05	7.35e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IGF1R—adrenal gland cancer	1.33e-05	7.31e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IGF1R—adrenal gland cancer	1.32e-05	7.24e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—BAD—adrenal gland cancer	1.32e-05	7.23e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—CTNNB1—adrenal gland cancer	1.31e-05	7.2e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—CTNNB1—adrenal gland cancer	1.31e-05	7.17e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—POMC—adrenal gland cancer	1.3e-05	7.14e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—CTNNB1—adrenal gland cancer	1.3e-05	7.12e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PRKACA—adrenal gland cancer	1.3e-05	7.11e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CDC42—adrenal gland cancer	1.29e-05	7.07e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—BAD—adrenal gland cancer	1.28e-05	7.05e-05	CbGpPWpGaD
Nilotinib—CA4—Metabolism—PTGS2—adrenal gland cancer	1.28e-05	7.05e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Biological oxidations—POMC—adrenal gland cancer	1.28e-05	7.03e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—CTNNB1—adrenal gland cancer	1.27e-05	6.99e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CTNNB1—adrenal gland cancer	1.27e-05	6.99e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—CTNNB1—adrenal gland cancer	1.27e-05	6.97e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PRKACA—adrenal gland cancer	1.27e-05	6.96e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CDC42—adrenal gland cancer	1.26e-05	6.91e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TERT—adrenal gland cancer	1.26e-05	6.91e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—BAD—adrenal gland cancer	1.25e-05	6.87e-05	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—EGFR—adrenal gland cancer	1.24e-05	6.83e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—CTNNB1—adrenal gland cancer	1.24e-05	6.83e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IGF2—adrenal gland cancer	1.24e-05	6.82e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—GNAS—adrenal gland cancer	1.23e-05	6.76e-05	CbGpPWpGaD
Nilotinib—CA2—Metabolism—PTGS2—adrenal gland cancer	1.23e-05	6.76e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CDC42—adrenal gland cancer	1.22e-05	6.7e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—BAD—adrenal gland cancer	1.22e-05	6.67e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—MED12—adrenal gland cancer	1.21e-05	6.64e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PRKACA—adrenal gland cancer	1.2e-05	6.61e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PRKACA—adrenal gland cancer	1.2e-05	6.6e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IGF1R—adrenal gland cancer	1.2e-05	6.59e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—RRM1—adrenal gland cancer	1.2e-05	6.57e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—SDHD—adrenal gland cancer	1.2e-05	6.57e-05	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—EGFR—adrenal gland cancer	1.2e-05	6.56e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—BAD—adrenal gland cancer	1.19e-05	6.53e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—BAD—adrenal gland cancer	1.19e-05	6.51e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—PTGS2—adrenal gland cancer	1.18e-05	6.48e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—EGFR—adrenal gland cancer	1.18e-05	6.47e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—EGFR—adrenal gland cancer	1.18e-05	6.46e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IGF2—adrenal gland cancer	1.18e-05	6.45e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—EGFR—adrenal gland cancer	1.17e-05	6.43e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—BRAF—adrenal gland cancer	1.17e-05	6.42e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—GNAS—adrenal gland cancer	1.17e-05	6.4e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—BAD—adrenal gland cancer	1.16e-05	6.37e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—BAD—adrenal gland cancer	1.16e-05	6.34e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—POMC—adrenal gland cancer	1.15e-05	6.33e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—GNAS—adrenal gland cancer	1.15e-05	6.32e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TERT—adrenal gland cancer	1.15e-05	6.29e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SDHB—adrenal gland cancer	1.14e-05	6.28e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—BRAF—adrenal gland cancer	1.14e-05	6.25e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IGF1R—adrenal gland cancer	1.14e-05	6.24e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TERT—adrenal gland cancer	1.14e-05	6.23e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—EGFR—adrenal gland cancer	1.13e-05	6.21e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ABCB1—adrenal gland cancer	1.13e-05	6.2e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—RRM1—adrenal gland cancer	1.13e-05	6.19e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SDHD—adrenal gland cancer	1.13e-05	6.19e-05	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	1.13e-05	6.19e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SDHD—adrenal gland cancer	1.12e-05	6.14e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—RRM1—adrenal gland cancer	1.12e-05	6.14e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—EGFR—adrenal gland cancer	1.12e-05	6.12e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—EGFR—adrenal gland cancer	1.11e-05	6.11e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—BRAF—adrenal gland cancer	1.11e-05	6.07e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—BAD—adrenal gland cancer	1.1e-05	6.04e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CDC42—adrenal gland cancer	1.1e-05	6.03e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—POMC—adrenal gland cancer	1.1e-05	6.02e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—BAD—adrenal gland cancer	1.09e-05	6.01e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—BRAF—adrenal gland cancer	1.08e-05	5.95e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	1.08e-05	5.93e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CDC42—adrenal gland cancer	1.08e-05	5.91e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—CTNNB1—adrenal gland cancer	1.08e-05	5.9e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—EGFR—adrenal gland cancer	1.06e-05	5.83e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IGF2—adrenal gland cancer	1.06e-05	5.81e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—GNAS—adrenal gland cancer	1.05e-05	5.76e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PRKACA—adrenal gland cancer	1.04e-05	5.71e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—EGFR—adrenal gland cancer	1.04e-05	5.7e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—PTGS2—adrenal gland cancer	1.04e-05	5.69e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—PTGS2—adrenal gland cancer	1.04e-05	5.69e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IGF2—adrenal gland cancer	1.04e-05	5.69e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—EGFR—adrenal gland cancer	1.03e-05	5.68e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TERT—adrenal gland cancer	1.03e-05	5.67e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—EGFR—adrenal gland cancer	1.03e-05	5.64e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—GNAS—adrenal gland cancer	1.03e-05	5.64e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—MED12—adrenal gland cancer	1.02e-05	5.62e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IGF1R—adrenal gland cancer	1.02e-05	5.62e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDC42—adrenal gland cancer	1.02e-05	5.6e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—EGFR—adrenal gland cancer	1.02e-05	5.6e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CTNNB1—adrenal gland cancer	1.01e-05	5.57e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TERT—adrenal gland cancer	1.01e-05	5.55e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—EGFR—adrenal gland cancer	1.01e-05	5.54e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—EGFR—adrenal gland cancer	1.01e-05	5.54e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—EGFR—adrenal gland cancer	1.01e-05	5.52e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IGF1R—adrenal gland cancer	1e-05	5.5e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—EGFR—adrenal gland cancer	9.98e-06	5.48e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—BAD—adrenal gland cancer	9.97e-06	5.47e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—BRAF—adrenal gland cancer	9.97e-06	5.47e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—BAD—adrenal gland cancer	9.88e-06	5.42e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—EGFR—adrenal gland cancer	9.85e-06	5.41e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IGF2—adrenal gland cancer	9.83e-06	5.4e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TERT—adrenal gland cancer	9.78e-06	5.37e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—GNAS—adrenal gland cancer	9.76e-06	5.36e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—GNAS—adrenal gland cancer	9.74e-06	5.35e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TP53—adrenal gland cancer	9.69e-06	5.32e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TP53—adrenal gland cancer	9.65e-06	5.3e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ABCB1—adrenal gland cancer	9.58e-06	5.26e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—BAD—adrenal gland cancer	9.52e-06	5.22e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IGF1R—adrenal gland cancer	9.5e-06	5.22e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—PTGS2—adrenal gland cancer	9.44e-06	5.18e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—CTNNB1—adrenal gland cancer	9.28e-06	5.09e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—POMC—adrenal gland cancer	9.19e-06	5.05e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TP53—adrenal gland cancer	9.19e-06	5.04e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	9.16e-06	5.03e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—CTNNB1—adrenal gland cancer	9.15e-06	5.02e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—POMC—adrenal gland cancer	9.11e-06	5e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—BRAF—adrenal gland cancer	9.08e-06	4.98e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	9.07e-06	4.98e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—BAD—adrenal gland cancer	8.99e-06	4.94e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PTGS2—adrenal gland cancer	8.94e-06	4.91e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MED12—adrenal gland cancer	8.92e-06	4.9e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PRKACA—adrenal gland cancer	8.83e-06	4.85e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDC42—adrenal gland cancer	8.82e-06	4.84e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TERT—adrenal gland cancer	8.81e-06	4.84e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—BAD—adrenal gland cancer	8.79e-06	4.82e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CTNNB1—adrenal gland cancer	8.66e-06	4.75e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TERT—adrenal gland cancer	8.63e-06	4.74e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—EGFR—adrenal gland cancer	8.52e-06	4.68e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—BAD—adrenal gland cancer	8.51e-06	4.67e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IGF2—adrenal gland cancer	8.5e-06	4.67e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—CTNNB1—adrenal gland cancer	8.45e-06	4.64e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—GNAS—adrenal gland cancer	8.42e-06	4.63e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MED12—adrenal gland cancer	8.41e-06	4.62e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MED12—adrenal gland cancer	8.34e-06	4.58e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—POMC—adrenal gland cancer	8.29e-06	4.55e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CTNNB1—adrenal gland cancer	8.23e-06	4.52e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IGF1R—adrenal gland cancer	8.22e-06	4.51e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—BRAF—adrenal gland cancer	8.18e-06	4.49e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TERT—adrenal gland cancer	8.18e-06	4.49e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—EGFR—adrenal gland cancer	8.18e-06	4.49e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PTGS2—adrenal gland cancer	8.05e-06	4.42e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—EGFR—adrenal gland cancer	8.04e-06	4.41e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—BRAF—adrenal gland cancer	8e-06	4.39e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CTNNB1—adrenal gland cancer	8e-06	4.39e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—adrenal gland cancer	7.94e-06	4.36e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—POMC—adrenal gland cancer	7.85e-06	4.31e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CTNNB1—adrenal gland cancer	7.83e-06	4.3e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CTNNB1—adrenal gland cancer	7.8e-06	4.28e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—BRAF—adrenal gland cancer	7.75e-06	4.25e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—POMC—adrenal gland cancer	7.75e-06	4.25e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—BAD—adrenal gland cancer	7.67e-06	4.21e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CTNNB1—adrenal gland cancer	7.64e-06	4.19e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CTNNB1—adrenal gland cancer	7.6e-06	4.17e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—BAD—adrenal gland cancer	7.51e-06	4.12e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PRKACA—adrenal gland cancer	7.47e-06	4.1e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	7.45e-06	4.09e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—RRM1—adrenal gland cancer	7.37e-06	4.05e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SDHD—adrenal gland cancer	7.37e-06	4.05e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—EGFR—adrenal gland cancer	7.35e-06	4.04e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	7.3e-06	4.01e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—EGFR—adrenal gland cancer	7.25e-06	3.98e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CTNNB1—adrenal gland cancer	7.24e-06	3.98e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CTNNB1—adrenal gland cancer	7.2e-06	3.95e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GNAS—adrenal gland cancer	7.15e-06	3.93e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—BAD—adrenal gland cancer	7.12e-06	3.91e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TERT—adrenal gland cancer	7.07e-06	3.88e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—POMC—adrenal gland cancer	7.07e-06	3.88e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ABCB1—adrenal gland cancer	7.02e-06	3.85e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—BRAF—adrenal gland cancer	6.98e-06	3.83e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—POMC—adrenal gland cancer	6.92e-06	3.8e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—EGFR—adrenal gland cancer	6.86e-06	3.77e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—BRAF—adrenal gland cancer	6.83e-06	3.75e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—EGFR—adrenal gland cancer	6.69e-06	3.67e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—POMC—adrenal gland cancer	6.57e-06	3.61e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—POMC—adrenal gland cancer	6.56e-06	3.6e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CTNNB1—adrenal gland cancer	6.56e-06	3.6e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—EGFR—adrenal gland cancer	6.52e-06	3.58e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PRKACA—adrenal gland cancer	6.51e-06	3.57e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CTNNB1—adrenal gland cancer	6.5e-06	3.57e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—BRAF—adrenal gland cancer	6.48e-06	3.56e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTGS2—adrenal gland cancer	6.46e-06	3.55e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—EGFR—adrenal gland cancer	6.33e-06	3.48e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CTNNB1—adrenal gland cancer	6.26e-06	3.44e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EGFR—adrenal gland cancer	6.2e-06	3.4e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—EGFR—adrenal gland cancer	6.18e-06	3.39e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTGS2—adrenal gland cancer	6.18e-06	3.39e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—BAD—adrenal gland cancer	6.15e-06	3.38e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PRKACA—adrenal gland cancer	6.14e-06	3.37e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PRKACA—adrenal gland cancer	6.08e-06	3.34e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GNAS—adrenal gland cancer	6.06e-06	3.33e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—EGFR—adrenal gland cancer	6.05e-06	3.32e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EGFR—adrenal gland cancer	6.02e-06	3.31e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	5.94e-06	3.26e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ABCB1—adrenal gland cancer	5.94e-06	3.26e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CTNNB1—adrenal gland cancer	5.92e-06	3.25e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CTNNB1—adrenal gland cancer	5.78e-06	3.17e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EGFR—adrenal gland cancer	5.74e-06	3.15e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EGFR—adrenal gland cancer	5.71e-06	3.13e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—POMC—adrenal gland cancer	5.67e-06	3.11e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—BRAF—adrenal gland cancer	5.6e-06	3.08e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CTNNB1—adrenal gland cancer	5.6e-06	3.07e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MED12—adrenal gland cancer	5.5e-06	3.02e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—adrenal gland cancer	5.48e-06	3.01e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GNAS—adrenal gland cancer	5.28e-06	2.9e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—adrenal gland cancer	5.24e-06	2.88e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—adrenal gland cancer	5.21e-06	2.86e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EGFR—adrenal gland cancer	5.2e-06	2.85e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EGFR—adrenal gland cancer	5.15e-06	2.83e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CTNNB1—adrenal gland cancer	5.04e-06	2.77e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GNAS—adrenal gland cancer	4.97e-06	2.73e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—adrenal gland cancer	4.96e-06	2.72e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CTNNB1—adrenal gland cancer	4.94e-06	2.71e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GNAS—adrenal gland cancer	4.93e-06	2.71e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ABCB1—adrenal gland cancer	4.88e-06	2.68e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ABCB1—adrenal gland cancer	4.84e-06	2.66e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—POMC—adrenal gland cancer	4.82e-06	2.64e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—adrenal gland cancer	4.69e-06	2.57e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CTNNB1—adrenal gland cancer	4.68e-06	2.57e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—adrenal gland cancer	4.58e-06	2.51e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—adrenal gland cancer	4.44e-06	2.44e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—adrenal gland cancer	4.36e-06	2.4e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—adrenal gland cancer	4.32e-06	2.37e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—POMC—adrenal gland cancer	4.08e-06	2.24e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CTNNB1—adrenal gland cancer	4.05e-06	2.22e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PRKACA—adrenal gland cancer	4.01e-06	2.2e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—adrenal gland cancer	4e-06	2.19e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—adrenal gland cancer	3.93e-06	2.16e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—adrenal gland cancer	3.91e-06	2.15e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—adrenal gland cancer	3.84e-06	2.11e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—adrenal gland cancer	3.72e-06	2.04e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—adrenal gland cancer	3.71e-06	2.04e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—POMC—adrenal gland cancer	3.55e-06	1.95e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—adrenal gland cancer	3.36e-06	1.84e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—POMC—adrenal gland cancer	3.35e-06	1.84e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—POMC—adrenal gland cancer	3.32e-06	1.82e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—adrenal gland cancer	3.29e-06	1.8e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—adrenal gland cancer	3.25e-06	1.79e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GNAS—adrenal gland cancer	3.25e-06	1.78e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—adrenal gland cancer	3.21e-06	1.76e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ABCB1—adrenal gland cancer	3.19e-06	1.75e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—adrenal gland cancer	3.11e-06	1.71e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—adrenal gland cancer	2.83e-06	1.56e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—adrenal gland cancer	2.69e-06	1.48e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—adrenal gland cancer	2.67e-06	1.47e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—adrenal gland cancer	2.65e-06	1.45e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—POMC—adrenal gland cancer	2.19e-06	1.2e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—adrenal gland cancer	1.75e-06	9.59e-06	CbGpPWpGaD
